Summary
Twenty-eight patients with advanced, measurable squamous carcinoma of the uterine cervix were treated with 62 courses of esorubicin at doses ranging from 20–35 mg/m2 every three weeks. All patients were evaluable for response and toxicity. All patients had received prior therapy including radiation therapy in 28, chemotherapy in 23, and surgery in 11. All patients were Gynecologic Oncology Group (GOG) performance status 0, 1 or 2. There were no responses seen. Severe (grade 3 or 4) leukopenia, thrombocytopenia, and anemia were seen in 13, 3, and 9 patients, respectively. Gastrointestinal toxicity as well as alopecia were the other adverse effects. Mucositis and phlebitis were not seen. Neither clinical congestive cardiomyopathy nor decrement in left ventricular ejection fraction was observed. Lack of response in association with moderate toxicity using this dose and schedule of esorubicin in squamous carcinoma of the cervix previously treated with chemotherapy makes further study as a salvage agent unwarranted.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arcamone F, Penco S, Redaelli S, Hanessian S: Synthesis and antitumor activity of 4′-deoxydaunorubicin and 4′-deoxyadriamycin. J Med Chem 19(12): 1424–1425, 1976
Salmon SE, Young L, Soehulen B, Liu R: Antitumor activity of esorubicin in human tumor clonogenic assay with comparison to doxorubicin. J Clin Oncol 2:282–286, 1984
Giuliani FC, Kaplan NO: New doxorubicin analogs active against doxorubicin resistant colon tumor xenograft in the nude mouse. Cancer Res 40:4682–4687, 1980
Casazza AM, Savi G, Pratesi G, DiMarco A: Antitumor activity in mice of 4′-deoxydoxorubicin in comparison to doxorubicin. Eur J Cancer Clin Oncol 19:411–418, 1983
Villani F, Comazzi R, Genitoni V: Preliminary evaluation of myocardial toxicity of 4′-deoxydoxorubicin: Experimental and clinical results. Drugs Explt Clin Res 3:223–231, 1985
Rozencweig M, Crespeigne N, Kenis Y: Phase I trial with 4′-deoxydoxorubicin (esorubicin). Invest New Drugs 1(4): 309–313, 1983
Garewal HS, Robertone A, Salmon SE, Jones SE, Alberts DS, Brooks R: Phase I trial of esorubicin (4′-deoxydoxorubicin). J Clin Oncol 2(9): 1034–1039, 1984
Locker GY, Hoeltgen T, Kilton L, Krauss S, McNamara M, Blough R, Johnson C: Phase II study of esorubicin in patients with advanced colorectal carcinoma and no prior chemotherapy: An Illinois Cancer Council trial. Cancer Treat Rep 71(7):765–766, 1987
Carlson RW, Billingham ME, Kohler M, Johnson FD, Doroshow JH, Torti FM: Esorubicin in refractory metastatic carcinoma of the breast: A Northern California Oncology Group study. Cancer Treat Rep 71(4):427–428, 1987
Zagonel V, Tirelli U, Vaccher E, Sorio R, Saracchini S, Monfardini S: Activity of 4′-deoxydoxorubicin (esorubicin) in patients with plasma cell tumors: A phase II study. Proc Fifth EORTC Symposium New Drugs, 1986
Kris MG, Gralla RJ, Burke MT, Fiore JJ, Kelsen DP, Marks LD, Heelan RT: Phase II trial of esorubicin in patients with advanced non-small cell lung cancer. Cancer Treat Rep 71(7):783–784, 1987
Frustaci S, Gasparini G, Veronesi A, Tirelli U, Pacciarini MA, Crivellari D, Zagonel V, Monfardini S: Phase II study of esorubicin (4′-deoxydoxorubicin) in locally advanced or metastatic head and neck carcinoma. Invest New Drugs 5:307–309, 1987
Braich T, Ahmann FR, Garewal HS, Robertone A, Salmon SE: Phase II trial of 4′-deoxydoxorubicin (esorubicin) in hormone resistant prostate cancer. Invest New Drugs 4(2): 193–196, 1986
Carlson RW, Williams RD, Billingham ME, Kohler M, Torti F: Phase II trial of esorubicin in the treatment of metastatic carcinoma of the kidney: A study of the Northern California Oncology Group. Cancer Treat 71(7):767–768, 1987
Frustaci S, Gasparini G, Galligioni E, Tirelli U, Di Pietro N, Crivellari D, Lo Re G, Monfardini S: Phase II trial of esorubicin in patients with advanced melanoma. Cancer Treat Rep 71(3):325–326, 1987
Ringenberg S, Propert K, Perry M, Weiss RB, Modeas C, Richards F, Graziano S, Hirsh V, Green M: Clinical cardiotoxicity of esorubicin: A prospective study with serial gaited heart scans and report of selected cases. Proc Am Soc Clin Oncol 6:83, 1987
Freedman RS, Herson J, Wharton JT, Rutledge FN: Single-agent chemotherapy for recurrent carcinoma of the cervix. Cancer Clin Trials 3(4):345–350, 1980
Wallace HJ, Hreshchyshyn MM, Wilbanks GD, Boronow RC, Fowler jr. WC, Blessing JA: Comparison of the therapeutic effects of adriamycin alone versus adriamycin plus vincristine versus adriamycin plus cyclophosphamide in the treatment of advanced carcinoma of the cervix. Cancer Treat Rep 62(10):1435–1441, 1978
Author information
Authors and Affiliations
Additional information
Address for offprints: GOG Headquarters, Suite 1945, 1234 Market Street, Philadelphia, PA 19107, USA.
Rights and permissions
About this article
Cite this article
McGuire, W.P., Blessing, J.A., Yordan, E. et al. Phase II study of esorubicin (4′-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: A Gynecologic Oncology Group study. Invest New Drugs 7, 235–238 (1989). https://doi.org/10.1007/BF00170865
Issue Date:
DOI: https://doi.org/10.1007/BF00170865